Clinical Trials Directory

Trials / Completed

CompletedNCT01535794

HPV Vaccine Acceptability Among Young Men Who Have Sex With Men

Exploring the Potential for Social Network Site-delivered Interventions to Increase HPV Vaccine Uptake Among Men Who Have Sex With Men

Status
Completed
Phase
Study type
Observational
Enrollment
2,000 (actual)
Sponsor
Indiana University · Academic / Other
Sex
Male
Age
18 Years – 26 Years
Healthy volunteers
Not accepted

Summary

The FDA has recently approved Gardasil for the prevention of anal cancer in people aged 9-26. Men who have sex with men (MSM) have disproportionately high rates of anal cancer and could benefit greatly from vaccination. Vaccine uptake among young MSM (YMSM) is poor, and little is known about factors associated with vaccine acceptance in this population. With the risk of anal cancer among MSM higher than the risk of cervical cancer among women before routine cytological screening was introduced, acceptance of a prophylactic vaccine in this subgroup is the most cost-effective and attainable strategy to greatly reduce the prevalence of anal cancer. While the investigators can assume the human papillomavirus (HPV) vaccine has many acceptable concepts among these men, there are multiple barriers which may potentially interfere with their likelihood of initiating the vaccine series. Vaccine catch-up rates among women of a similar age has been poor, and there is no reason to expect this to be higher among men. One potential strategy to increase vaccine uptake in this catch-up group is to implement a patient-driven program to promote vaccination among men. This project will contribute to the investigators understanding of how the investigators can utilize social networks to identify barriers to HPV vaccination among YMSM, and how to potentially influence a patient-driven vaccination effort to increase uptake among men in the catch-up age group. This research will inform future interventions to targeted populations that may be incorporated into online social networking websites to encourage HPV vaccination.

Conditions

Timeline

Start date
2012-02-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2012-02-20
Last updated
2014-08-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01535794. Inclusion in this directory is not an endorsement.